Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects

Immune checkpoint inhibitors (ICIs) are effective against advanced and even perioperative non-small-cell lung cancer (NSCLC) and result in durable clinical benefit, regardless of programmed death ligand-1 (PD-L1) expression status in cancer. Existing clinical evidence shows that the effect of immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Chunyan, Wang, Yan, Xue, Jianxin, Zhou, Xiaojuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353115/
https://www.ncbi.nlm.nih.gov/pubmed/35935943
http://dx.doi.org/10.3389/fimmu.2022.940288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353115/
https://www.ncbi.nlm.nih.gov/pubmed/35935943
http://dx.doi.org/10.3389/fimmu.2022.940288

Ejemplares similares